These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


169 related items for PubMed ID: 26657126

  • 1. [Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1].
    Minoura H, Iwai M, Taniuchi Y, Katashima M, Takahashi H.
    Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):342-8. PubMed ID: 26657126
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S, Baumann U.
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia.
    Äärelä L, Nevalainen PI, Kurppa K, Hiltunen P.
    J Pediatr Endocrinol Metab; 2020 May 26; 33(5):661-664. PubMed ID: 32238608
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Drug to treat rare pediatric liver disease.
    FDA Consum; 2002 May 26; 36(2):5. PubMed ID: 11989476
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
    Hanauske-Abel HM, Popowicz A, Remotti H, Newfield RS, Levy J.
    J Pediatr Gastroenterol Nutr; 2002 Jul 26; 35(1):73-8. PubMed ID: 12142814
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Outcome of children with hereditary tyrosinaemia following newborn screening.
    McKiernan PJ, Preece MA, Chakrapani A.
    Arch Dis Child; 2015 Aug 26; 100(8):738-41. PubMed ID: 25564536
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.
    Thimm E, Herebian D, Assmann B, Klee D, Mayatepek E, Spiekerkoetter U.
    Mol Genet Metab; 2011 Feb 26; 102(2):122-5. PubMed ID: 21112803
    [Abstract] [Full Text] [Related]

  • 20. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment.
    van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA.
    J Pediatr Gastroenterol Nutr; 2005 Jan 26; 40(1):90-3. PubMed ID: 15625434
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.